Phase II study of vindesine in patients with metastatic breast cancer.

Abstract

Twenty-six patients with far-advanced, refractory breast cancer were treated iv with vindesine (DVA) at a dose of 3 mg/m2/week. In 21 evaluable patients there were six partial remissions. Four patients who did not respond after at least four doses of intermittent DVA received continuous-infusion DVA at a dose of 1.5 mg/m2/day X 2 every other week; none responded. Five of the six responders had had disease progression on other vinca alkaloids. Leukopenia and neuromuscular toxicity were dose-limiting.

• Authors: M A Cobleigh, S D Williams, L H Einhorn
• Journal: Cancer treatment reports (Cancer Treat Rep) 1981 Jul-Aug Vol. 65 Issue 7-8 Pg. 659-63 ISSN: 0361-5960 [Print] United States
• PMID: 7248983 (Publication Type: Journal Article)

Chemical References

• Vinblastine
• Vindesine

Topics

• Breast Neoplasms (drug therapy)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Humans
• Leukopenia (chemically induced)
• Neoplasm Metastasis
• Neuromuscular Diseases (chemically induced)
• Prognosis
• Vinblastine (adverse effects, analogs & derivatives, therapeutic use)
• Vindesine